Peanut (Arachis hypogaea) allergen powder-dnfp (Palforzia™) in peanut allergy: a profile of its use
Funding The preparation of this review was not supported by any external funding.
Authorship and conflict of interest Young-A Heo, a salaried employee of Adis International Ltd/Springer Nature and an editor of Drugs & Therapy Perspectives, was not involved in any publishing decisions for the manuscript and declares no declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content
Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.
Additional information about this Adis Drug
Review can be found here.
(Arachis hypogaea) allergen
powder-dnfp (Palforzia™; hereafter referred to as PTAH), is
the first oral immunotherapy approved in the USA and European Commission for mitigating allergic
reactions in children aged 4–17 years with peanut allergy. In the pivotal phase
3 studies in patients with peanut allergy, relative to placebo, PTAH significantly
desensitized to peanut protein and reduced severity of allergic reactions to
accidental peanut exposure, together with improvements in food allergy-related quality of life. The clinical benefits of PTAH were
maintained with continued treatment for up to 2 years. Most adverse events with PTAH, including systemic allergic
reactions, were of mild to moderate severity. Frequency and
severity of adverse events decreased with continued treatment.
© Springer Nature Switzerland AG 2021